Is D-Lysergic acid-L-propanolamide Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use D-Lysergic acid-L-propanolamide? Is D-Lysergic acid-L-propanolamide safe for nursing mother and child? Does D-Lysergic acid-L-propanolamide extracts into breast milk? Does D-Lysergic acid-L-propanolamide has any long term or short term side effects on infants? Can D-Lysergic acid-L-propanolamide influence milk supply or can D-Lysergic acid-L-propanolamide decrease milk supply in lactating mothers?

D-Lysergic acid-L-propanolamide given in the immediate postpartum period lowers serum basal prolactin and possibly suckling-induced prolactin increases. It also appears to decrease the rate of breastfeeding. D-Lysergic acid-L-propanolamide is probably best avoided in mothers who wish to nurse, relying instead on suckling-induced oxytocin release to hasten uterine involution. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

In one study, a single oral dose of D-Lysergic acid-L-propanolamide maleate 0.2 mg in 12 nonbreastfeeding women on day 3 postpartum caused a 10 to 20% drop in average serum prolactin levels between 0.5 and 2.5 hours after the dose. The authors expressed concern that repeated doses of D-Lysergic acid-L-propanolamide could suppress lactation.[1] Ten women who were given D-Lysergic acid-L-propanolamide 0.2 mg 3 times daily from day 1 to 7 postpartum were compared to 6 women who did not receive the drug. None of the women breastfed their infants. Serum prolactin levels were significantly lower in the treated women by day 2 postpartum and persisted through the 7 days of the study. Seven of the 10 treated women developed breast engorgement and had milk letdown and 3 had progressive inhibition of lactation. In 2 additional women who were nursing their infants, a single dose of 0.2 mg of D-Lysergic acid-L-propanolamide intravenously blunted the response of serum prolactin to suckling.[2] In a nonrandomized study, 11 women with normal deliveries were given an intramuscular injection of either oxytocin 5 units plus D-Lysergic acid-L-propanolamide 0.5 mg (n = 5) or 5 units of oxytocin alone (n = 6). Serum prolactin levels were lower in the women given D-Lysergic acid-L-propanolamide from 0.5 to 2.5 hours.[3] In a randomized, but nonblinded, controlled trial, women thought to be at low risk of postpartum hemorrhage were given either D-Lysergic acid-L-propanolamide 0.5 mg intravenously following birth of the infant (n = 197) or no drug (n = 135). Serum prolactin levels obtained in the period of 48 to 72 hours postpartum did not differ between the groups, but fewer of those who received D-Lysergic acid-L-propanolamide were still breastfeeding at 4 weeks postpartum than those who did not.[4] In a randomized, but nonblinded, controlled trial, women thought to be at low risk of postpartum hemorrhage were given either D-Lysergic acid-L-propanolamide 0.5 mg intravenously following birth of the infant (n = 197) or no drug (n = 135). Serum prolactin levels obtained in the period of 48 to 72 hours postpartum did not differ between the groups, but fewer of those who received D-Lysergic acid-L-propanolamide were still breastfeeding at 4 weeks postpartum than those who did not.[4] A retrospective review of obstetrical records of 18,165 records of mothers giving birth in Wales found that use of intravenous or intramuscular D-Lysergic acid-L-propanolamide during the third stage of labor as a uterotonic reduced the odds of the mother breastfeeding at 48 hours postpartum. The reduction was 36% in the overall sample and 49% for primiparous mothers.[5]